TY - JOUR
T1 - Evaluation of a primary care-based collaborative care model (PARTNERS2) for people with diagnoses of schizophrenia, bipolar, or other psychoses: study protocol for a cluster randomised controlled trial
AU - Plappert, Humera
AU - Hobson-Merrett, Charley
AU - Gibbons, Bliss
AU - Baker, Elina
AU - Bevan, Sheridan
AU - Clark, Michael
AU - Creanor, Siobhan
AU - Davies, Linda
AU - Denyer, Rebecca
AU - Frost, Julia
AU - Gask, Linda
AU - Gibson, John
AU - Gill, Laura
AU - Gwernan-Jones, Ruth
AU - Hardy, Pollyanna
AU - Hosking, Joanne
AU - Huxley, Peter
AU - Jeffrey, Alison
AU - Jones, Benjamin
AU - Marwaha, Steven
AU - Pinold, Vanessa
AU - Planner, Claire
AU - Rawcliffe, Tim
AU - Reilly, Siobhan
AU - Richards, Debra
AU - Williams, Lynsey
AU - Birchwood, Max
AU - Byng, Richard
PY - 2021/6
Y1 - 2021/6
N2 - BackgroundCurrent NHS policy encourages an integrated approach to provision of mental and physical care for individuals with long term mental health problems. The ‘PARTNERS2’ complex intervention is designed to support individuals with psychosis in a primary care setting.AimThe trial will evaluate the clinical and cost-effectiveness of the PARTNERS2 intervention.Design & settingThis is a cluster randomised controlled superiority trial comparing collaborative care (PARTNERS2) with usual care, with an internal pilot to assess feasibility. The setting will be primary care within four trial recruitment areas: Birmingham & Solihull, Cornwall, Plymouth, and Somerset. GP practices are randomised 1:1 to either (a) the PARTNERS2 intervention plus modified standard care (‘intervention’); or (b) standard care only (‘control’).MethodPARTNERS2 is a flexible, general practice-based, person-centred, coaching-based intervention aimed at addressing mental health, physical health, and social care needs. Two hundred eligible individuals from 39 GP practices are taking part. They were recruited through identification from secondary and primary care databases. The primary hypothesis is quality of life (QOL). Secondary outcomes include: mental wellbeing, time use, recovery, and process of physical care. A process evaluation will assess fidelity of intervention delivery, test hypothesised mechanisms of action, and look for unintended consequences. An economic evaluation will estimate its cost-effectiveness. Intervention delivery and follow-up have been modified during the COVID-19 pandemic.ConclusionThe overarching aim is to establish the clinical and cost-effectiveness of the model for adults with a diagnosis of schizophrenia, bipolar, or other types of psychoses.
AB - BackgroundCurrent NHS policy encourages an integrated approach to provision of mental and physical care for individuals with long term mental health problems. The ‘PARTNERS2’ complex intervention is designed to support individuals with psychosis in a primary care setting.AimThe trial will evaluate the clinical and cost-effectiveness of the PARTNERS2 intervention.Design & settingThis is a cluster randomised controlled superiority trial comparing collaborative care (PARTNERS2) with usual care, with an internal pilot to assess feasibility. The setting will be primary care within four trial recruitment areas: Birmingham & Solihull, Cornwall, Plymouth, and Somerset. GP practices are randomised 1:1 to either (a) the PARTNERS2 intervention plus modified standard care (‘intervention’); or (b) standard care only (‘control’).MethodPARTNERS2 is a flexible, general practice-based, person-centred, coaching-based intervention aimed at addressing mental health, physical health, and social care needs. Two hundred eligible individuals from 39 GP practices are taking part. They were recruited through identification from secondary and primary care databases. The primary hypothesis is quality of life (QOL). Secondary outcomes include: mental wellbeing, time use, recovery, and process of physical care. A process evaluation will assess fidelity of intervention delivery, test hypothesised mechanisms of action, and look for unintended consequences. An economic evaluation will estimate its cost-effectiveness. Intervention delivery and follow-up have been modified during the COVID-19 pandemic.ConclusionThe overarching aim is to establish the clinical and cost-effectiveness of the model for adults with a diagnosis of schizophrenia, bipolar, or other types of psychoses.
UR - https://pearl.plymouth.ac.uk/context/pms-research/article/1258/viewcontent/BJGPO.2021.0033.full.pdf
U2 - 10.3399/bjgpo.2021.0033
DO - 10.3399/bjgpo.2021.0033
M3 - Article
SN - 2398-3795
VL - 5
JO - BJGP Open
JF - BJGP Open
IS - 3
ER -